Professor Hendrik Bonnemeier
Schleswig-Holstein University Clinic, Lubeck Campus, Luebeck (Germany)
Renal function worsening in factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study
Event: ESC Congress 2019
Topic: Oral Anticoagulation
Session: Atrial fibrillation and oral anticoagulation 1
Are there shock incidence and mortality differences in primary prevention patients regarding device type and ischemia? A NORDIC ICD sub-study.
Event: ESC Congress 2019
Topic: Epidemiology, Prognosis, Outcome
Session: Heart failure devices: new approaches
Comparative effcomparative effectiveness and safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and malignant diseases, insights from the RELOADED study
Event: ESC Congress 2019
Topic: Oral Anticoagulation
Session: Atrial fibrillation and oral anticoagulation 4
Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study
Event: ESC Congress 2019
Topic: Oral Anticoagulation
Session: Atrial fibrillation and oral anticoagulation 6
State of the art in cardiac resynchronization therapy: how device features improve clinical outcomes
Event: ESC Congress 2019
Topic: Cardiac Resynchronisation Therapy (CRT)
Session: Heart failure in 2019: latest update on implantable device therapy
Think about the kidneys: why does renal function matter in patients with atrial fibrillation?
Event: ESC Congress 2019
Topic: Stroke Prevention
Session: The bigger picture in stroke prevention and anticoagulation: think beyond atrial fibrillation
Q&A and closing - Solving the puzzle of heart failure, diabetic kidney disease and risk of stroke: let’s fit the pieces together.
Event: Heart Failure 2019
Topic: Cardiovascular Disease in Special Populations
Session: Solving the puzzle of heart failure, diabetic kidney disease and risk of stroke: let’s fit the pieces together
Interlinked factors affecting stroke risk in your patients with AF.
Event: Heart Failure 2019
Topic: Atrial Fibrillation (AF)
Session: Solving the puzzle of heart failure, diabetic kidney disease and risk of stroke: let’s fit the pieces together
Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study
Event: ESC Congress 2017
Topic: Atrial fibrillation (AF)
Session: Stroke prevention
Characteristics of 15mg od rivaroxaban patients from the RELOAD study
Event: ESC Congress 2017
Topic: Atrial fibrillation (AF)
Session: Stroke prevention
ESC 365 is supported by
